Tag Archives: viral

#432027 We Read This 800-Page Report on the ...

The longevity field is bustling but still fragmented, and the “silver tsunami” is coming.

That is the takeaway of The Science of Longevity, the behemoth first volume of a four-part series offering a bird’s-eye view of the longevity industry in 2017. The report, a joint production of the Biogerontology Research Foundation, Deep Knowledge Life Science, Aging Analytics Agency, and Longevity.International, synthesizes the growing array of academic and industry ventures related to aging, healthspan, and everything in between.

This is huge, not only in scale but also in ambition. The report, totally worth a read here, will be followed by four additional volumes in 2018, covering topics ranging from the business side of longevity ventures to financial systems to potential tensions between life extension and religion.

And that’s just the first step. The team hopes to publish updated versions of the report annually, giving scientists, investors, and regulatory agencies an easy way to keep their finger on the longevity pulse.

“In 2018, ‘aging’ remains an unnamed adversary in an undeclared war. For all intents and purposes it is mere abstraction in the eyes of regulatory authorities worldwide,” the authors write.

That needs to change.

People often arrive at the field of aging from disparate areas with wildly diverse opinions and strengths. The report compiles these individual efforts at cracking aging into a systematic resource—a “periodic table” for longevity that clearly lays out emerging trends and promising interventions.

The ultimate goal? A global framework serving as a road map to guide the burgeoning industry. With such a framework in hand, academics and industry alike are finally poised to petition the kind of large-scale investments and regulatory changes needed to tackle aging with a unified front.

Infographic depicting many of the key research hubs and non-profits within the field of geroscience.
Image Credit: Longevity.International
The Aging Globe
The global population is rapidly aging. And our medical and social systems aren’t ready to handle this oncoming “silver tsunami.”

Take the medical field. Many age-related diseases such as Alzheimer’s lack effective treatment options. Others, including high blood pressure, stroke, lung or heart problems, require continuous medication and monitoring, placing enormous strain on medical resources.

What’s more, because disease risk rises exponentially with age, medical care for the elderly becomes a game of whack-a-mole: curing any individual disease such as cancer only increases healthy lifespan by two to three years before another one hits.

That’s why in recent years there’s been increasing support for turning the focus to the root of the problem: aging. Rather than tackling individual diseases, geroscience aims to add healthy years to our lifespan—extending “healthspan,” so to speak.

Despite this relative consensus, the field still faces a roadblock. The US FDA does not yet recognize aging as a bona fide disease. Without such a designation, scientists are banned from testing potential interventions for aging in clinical trials (that said, many have used alternate measures such as age-related biomarkers or Alzheimer’s symptoms as a proxy).

Luckily, the FDA’s stance is set to change. The promising anti-aging drug metformin, for example, is already in clinical trials, examining its effect on a variety of age-related symptoms and diseases. This report, and others to follow, may help push progress along.

“It is critical for investors, policymakers, scientists, NGOs, and influential entities to prioritize the amelioration of the geriatric world scenario and recognize aging as a critical matter of global economic security,” the authors say.

Biomedical Gerontology
The causes of aging are complex, stubborn, and not all clear.

But the report lays out two main streams of intervention with already promising results.

The first is to understand the root causes of aging and stop them before damage accumulates. It’s like meddling with cogs and other inner workings of a clock to slow it down, the authors say.

The report lays out several treatments to keep an eye on.

Geroprotective drugs is a big one. Often repurposed from drugs already on the market, these traditional small molecule drugs target a wide variety of metabolic pathways that play a role in aging. Think anti-oxidants, anti-inflammatory, and drugs that mimic caloric restriction, a proven way to extend healthspan in animal models.

More exciting are the emerging technologies. One is nanotechnology. Nanoparticles of carbon, “bucky-balls,” for example, have already been shown to fight viral infections and dangerous ion particles, as well as stimulate the immune system and extend lifespan in mice (though others question the validity of the results).

Blood is another promising, if surprising, fountain of youth: recent studies found that molecules in the blood of the young rejuvenate the heart, brain, and muscles of aged rodents, though many of these findings have yet to be replicated.

Rejuvenation Biotechnology
The second approach is repair and maintenance.

Rather than meddling with inner clockwork, here we force back the hands of a clock to set it back. The main example? Stem cell therapy.

This type of approach would especially benefit the brain, which harbors small, scattered numbers of stem cells that deplete with age. For neurodegenerative diseases like Alzheimer’s, in which neurons progressively die off, stem cell therapy could in theory replace those lost cells and mend those broken circuits.

Once a blue-sky idea, the discovery of induced pluripotent stem cells (iPSCs), where scientists can turn skin and other mature cells back into a stem-like state, hugely propelled the field into near reality. But to date, stem cells haven’t been widely adopted in clinics.

It’s “a toolkit of highly innovative, highly invasive technologies with clinical trials still a great many years off,” the authors say.

But there is a silver lining. The boom in 3D tissue printing offers an alternative approach to stem cells in replacing aging organs. Recent investment from the Methuselah Foundation and other institutions suggests interest remains high despite still being a ways from mainstream use.

A Disruptive Future
“We are finally beginning to see an industry emerge from mankind’s attempts to make sense of the biological chaos,” the authors conclude.

Looking through the trends, they identified several technologies rapidly gaining steam.

One is artificial intelligence, which is already used to bolster drug discovery. Machine learning may also help identify new longevity genes or bring personalized medicine to the clinic based on a patient’s records or biomarkers.

Another is senolytics, a class of drugs that kill off “zombie cells.” Over 10 prospective candidates are already in the pipeline, with some expected to enter the market in less than a decade, the authors say.

Finally, there’s the big gun—gene therapy. The treatment, unlike others mentioned, can directly target the root of any pathology. With a snip (or a swap), genetic tools can turn off damaging genes or switch on ones that promote a youthful profile. It is the most preventative technology at our disposal.

There have already been some success stories in animal models. Using gene therapy, rodents given a boost in telomerase activity, which lengthens the protective caps of DNA strands, live healthier for longer.

“Although it is the prospect farthest from widespread implementation, it may ultimately prove the most influential,” the authors say.

Ultimately, can we stop the silver tsunami before it strikes?

Perhaps not, the authors say. But we do have defenses: the technologies outlined in the report, though still immature, could one day stop the oncoming tidal wave in its tracks.

Now we just have to bring them out of the lab and into the real world. To push the transition along, the team launched Longevity.International, an online meeting ground that unites various stakeholders in the industry.

By providing scientists, entrepreneurs, investors, and policy-makers a platform for learning and discussion, the authors say, we may finally generate enough drive to implement our defenses against aging. The war has begun.

Read the report in full here, and watch out for others coming soon here. The second part of the report profiles 650 (!!!) longevity-focused research hubs, non-profits, scientists, conferences, and literature. It’s an enormously helpful resource—totally worth keeping it in your back pocket for future reference.

Image Credit: Worraket / Shutterstock.com Continue reading

Posted in Human Robots

#431023 Finish Him! MegaBots’ Giant Robot Duel ...

It began two years ago when MegaBots co-founders Matt Oehrlein and Gui Cavalcanti donned American flags as capes and challenged Suidobashi Heavy Industries to a giant robot duel in a YouTube video that immediately went viral.
The battle proposed: MegaBots’ 15-foot tall, 1,200-pound MK2 robot vs. Suidobashi’s 9,000-pound robot, KURATAS. Oehrlein and Cavalcanti first discovered the KURATAS robot in a listing on Amazon with a million-dollar price tag.
In an equally flamboyant response video, Suidobashi CEO and founder Kogoro Kurata accepted the challenge. (Yes, he named his robot after himself.) Both parties planned to take a year to prepare their robots for combat.
In the end, it took twice the amount of time. Nonetheless, the battle is going down this September in an undisclosed location.
Oehrlein shared more about the much-anticipated showdown during our interview at Singularity University’s Global Summit.

Two years since the initial video, MegaBots has now completed the combat-capable MK3 robot, named Eagle Prime. This new 12-ton, 16-foot-tall robot is powered by a 430-horsepower Corvette engine and requires two human pilots.
It’s also the robot they recently shipped to take on KURATAS.

Building Eagle Prime has been no small feat. With arms and legs that each weigh as much as a car, assembling the robot takes forklifts, cranes, and a lot of caution. Fortress One, MegaBots’ headquarters in Hayward, California is where the magic happens.
In terms of “weaponry,” Eagle Prime features a giant pneumatic cannon that shoots huge paint cannonballs. Oehrlein warns, “They can shatter all the windows in a car. It’s very powerful.” A logging grapple, which looks like a giant claw and exerts 3,000 pounds of steel-crushing force, has also been added to the robot.

“It’s a combination of range combat, using the paint balls to maybe blind cameras on the other robot or take out sensitive electronics, and then closing in with the claw and trying to disable their systems at close range,” Oehrlein explains.
Safety systems include a cockpit roll cage for the two pilots, five-point safety seatbelt harnesses, neck restraints, helmets, and flame retardant suits.
Co-founder, Matt Oehrlein, inside the cockpit of MegaBots’ Eagle Prime giant robot.
Oehrlein and Cavalcanti have also spent considerable time inside Eagle Prime practicing battlefield tactics and maneuvering the robot through obstacle courses.
Suidobashi’s robot is a bit shorter and lighter, but also a little faster, so the battle dynamics should be interesting.
You may be thinking, “Why giant dueling robots?”
MegaBots’ grand vision is a full-blown international sports league of giant fighting robots on the scale of Formula One racing. Picture a nostalgic evening sipping a beer (or three) and watching Pacific Rim- and Power Rangers-inspired robots battle—only in real life.
Eagle Prime is, in good humor, a proudly patriotic robot.
“Japan is known as a robotic powerhouse,” says Oehrlein, “I think there’s something interesting about the slightly overconfident American trying to get a foothold in the robotics space and doing it by building a bigger, louder, heavier robot, in true American fashion.”
For safety reasons, no fans will be admitted during the time of the fight. The battle will be posted after the fact on MegaBots’ YouTube channel and Facebook page.
We’ll soon find out whether this becomes another American underdog story.
In the meantime, I give my loyalty to MegaBots, and in the words of Mortal Kombat, say, “Finish him!”

via GIPHY
Image Credit: MegaBots Continue reading

Posted in Human Robots

#431015 Finish Him! MegaBots’ Giant Robot Duel ...

It began two years ago when MegaBots co-founders Matt Oehrlein and Gui Cavalcanti donned American flags as capes and challenged Suidobashi Heavy Industries to a giant robot duel in a YouTube video that immediately went viral.
The battle proposed: MegaBots’ 15-foot tall, 1,200-pound MK2 robot vs. Suidobashi’s 9,000-pound robot, KURATAS. Oehrlein and Cavalcanti first discovered the KURATAS robot in a listing on Amazon with a million-dollar price tag.
In an equally flamboyant response video, Suidobashi CEO and founder Kogoro Kurata accepted the challenge. (Yes, he named his robot after himself.) Both parties planned to take a year to prepare their robots for combat.
In the end, it took twice the amount of time. Nonetheless, the battle is going down this September in an undisclosed location in Japan.
Oehrlein shared more about the much-anticipated showdown during our interview at Singularity University’s Global Summit.

Two years since the initial video, MegaBots has now completed the combat-capable MK3 robot, named Eagle Prime. This new 12-ton, 16-foot-tall robot is powered by a 430-horsepower Corvette engine and requires two human pilots.
It’s also the robot they recently shipped to Japan to take on KURATAS.

Building Eagle Prime has been no small feat. With arms and legs that each weigh as much as a car, assembling the robot takes forklifts, cranes, and a lot of caution. Fortress One, MegaBots’ headquarters in Hayward, California is where the magic happens.
In terms of “weaponry,” Eagle Prime features a giant pneumatic cannon that shoots huge paint cannonballs. Oehrlein warns, “They can shatter all the windows in a car. It’s very powerful.” A logging grapple, which looks like a giant claw and exerts 3,000 pounds of steel-crushing force, has also been added to the robot.
“It’s a combination of range combat, using the paint balls to maybe blind cameras on the other robot or take out sensitive electronics, and then closing in with the claw and trying to disable their systems at close range,” Oehrlein explains.
Safety systems include a cockpit roll cage for the two pilots, five-point safety seatbelt harnesses, neck restraints, helmets, and flame retardant suits.
Co-founder, Matt Oehrlein, inside the cockpit of MegaBots’ Eagle Prime giant robot.
Oehrlein and Cavalcanti have also spent considerable time inside Eagle Prime practicing battlefield tactics and maneuvering the robot through obstacle courses.
Suidobashi’s robot is a bit shorter and lighter, but also a little faster, so the battle dynamics should be interesting.
You may be thinking, “Why giant dueling robots?”
MegaBots’ grand vision is a full-blown international sports league of giant fighting robots on the scale of Formula One racing. Picture a nostalgic evening sipping a beer (or three) and watching Pacific Rim- and Power Rangers-inspired robots battle—only in real life.
Eagle Prime is, in good humor, a proudly patriotic robot.
“Japan is known as a robotic powerhouse,” says Oehrlein, “I think there’s something interesting about the slightly overconfident American trying to get a foothold in the robotics space and doing it by building a bigger, louder, heavier robot, in true American fashion.”
For safety reasons, no fans will be admitted during the time of the fight. The battle will be posted after the fact on MegaBots’ YouTube channel and Facebook page.
We’ll soon find out whether this becomes another American underdog story.
In the meantime, I give my loyalty to MegaBots, and in the words of Mortal Kombat, say, “Finish him!”

via GIPHY
Image Credit: MegaBots Continue reading

Posted in Human Robots